Clinical Trials Browser

Triple Negative Breast Neoplasms × trastuzumab duocarmazine × 30 days × Clear all

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms